SEZ6-Targeting ADC ABBV-706 in Advanced SCLC & Solid Tumors: Phase 1 Trial Update

ABBV-706, a SEZ6-targeting antibody-drug conjugate, demonstrates preliminary efficacy in phase 1 trials for advanced small cell lung cancer and solid tumors.
Adverse events reported include grade 3/4 neutropenia and thrombocytopenia, with dose-limiting toxicities observed in a portion of participants.
Funding by AbbVie and collaboration with the National Cancer Institute highlight industry-academia partnerships in oncology innovation.

Phase 1 Trial Results for ABBV-706 in Advanced Cancers

Phase 1 trial data for ABBV-706, an antibody-drug conjugate targeting the SEZ6 protein, were published in Nature Medicine on 29 June 2026, following an author correction. According to the corrected analysis, a significant proportion of patients achieved stable disease, with a median progression-free survival of 4.2 months. The trial was funded by AbbVie, with additional support from the National Cancer Institute (NCI) under grant R01CA243210.

Biological Mechanism and Clinical Context

SEZ6, a cell adhesion molecule, is overexpressed in SCLC and certain solid tumors, contributing to tumor proliferation and metastasis. ABBV-706 binds to SEZ6-expressing cells, delivering a potent microtubule inhibitor payload. This mechanism differs from conventional chemotherapy by targeting tumor-specific antigens, potentially reducing off-target toxicity. Early data suggest ABBV-706 could address a critical unmet need."

Adverse Events and Dose Optimization

The trial identified dose-limiting toxicities (DLTs) in a portion of participants, primarily grade 3/4 neutropenia and thrombocytopenia. Researchers observed that a majority of patients required dose reductions, with a small percentage discontinuing treatment due to adverse events. The maximum tolerated dose (MTD) was established at 1.8 mg/kg every three weeks. The DLT profile aligns with other antibody-drug conjugates, but long-term monitoring is needed to assess cumulative toxicity."

Funding Transparency and Industry Collaboration

ABBV-706 was developed by AbbVie in partnership with the NCI, reflecting a growing trend of pharmaceutical companies collaborating with public health agencies to accelerate oncology research. The trial's funding structure, disclosed in the Nature Medicine correction, includes significant industry support and federal grants. "Industry-academia alliances like this bridge the gap between innovation and patient access," she stated.

EHA2026 | What are the updated 4-year results from the phase III DREAMM-7 trial in RRMM?

Directory Bridge: Clinical Triage for Emerging Therapies

Oncologists managing patients on ABBV-706 should consult [Relevant Diagnostic Center] for advanced biomarker testing to identify SEZ6 expression. Pharmaceutical companies developing antibody-drug conjugates may engage [Relevant Healthcare Compliance Attorney] to navigate regulatory pathways for novel therapeutic classes.

Future Directions and Regulatory Pathways

The trial’s authors are preparing for phase
=== END ARTICLE ===